The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial erlotinib, gemcitabine, and the hedgehog inhibitor, GDC-0449.
S. R. Palmer
No relevant relationships to disclose
C. Erlichman
No relevant relationships to disclose
M. Fernandez-Zapico
No relevant relationships to disclose
Y. Qi
No relevant relationships to disclose
L. Almada
No relevant relationships to disclose
A. McCleary-Wheeler
No relevant relationships to disclose
M. J. Borad
No relevant relationships to disclose
J. R. Molina
No relevant relationships to disclose
A. Grothey
Consultant or Advisory Role - Genentech (U); Roche (U)
Research Funding - Roche/Genentech
H. C. Pitot
No relevant relationships to disclose
A. Jatoi
No relevant relationships to disclose
D. W. Northfelt
No relevant relationships to disclose
R. R. McWilliams
No relevant relationships to disclose
S. H. Okuno
No relevant relationships to disclose
P. Haluska
Consultant or Advisory Role - Lilly (U); Roche (U)
Research Funding - ImClone Systems; Lilly; OSI Pharmaceuticals; Roche
G. P. Kim
No relevant relationships to disclose
G. Colon-Otero
No relevant relationships to disclose